Literature DB >> 31555681

Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy.

Linsen Ye1, Rongpu Liang1, Jiebin Zhang1, Chaojin Chen2, Xiaolong Chen1, Yi Zhang1, Guoying Wang1, Yang Yang1, Guihua Chen3,4.   

Abstract

BACKGROUND: The albumin-bilirubin (ALBI) grade is an index that could objectively evaluate liver function. The purpose of this study was to evaluate the prognostic value of postoperative ALBI (post-ALBI) grade and ALBI changes (△ALBI) after hepatectomy in patients with hepatocellular carcinoma (HCC).
METHODS: The clinical and pathological data of 300 patients with HCC who underwent hepatectomy in the Third Affiliated Hospital of Sun Yat-Sen University from January 19, 2009 to December 25, 2014, were analyzed retrospectively. According to the test data, the patients were divided into post-ALBI grade I, post-ALBI grade II, and post-ALBI grade III groups. According to the receiver operating characteristic curves (ROC), the patients were divided into △ALBI (△ALBI >0.71) high and low groups (△ALBI ≤0.71). Baseline clinical data, recurrence-free survival (RFS) and overall survival (OS) rates were compared between the groups.
RESULTS: The 1-, 3-, and 5-year RFS rates and OS rates of patients with post-ALBI grade III were significantly reduced in comparison to those with post-ALBI grade II (P<0.001 both). Between the △ALBI groups, patients with low △ALBI level had significantly reduced 1-, 3-, and 5-year RFS rates and OS rates compared to those with a high △ALBI level (P<0.001 both). Multivariate analyses indicated that higher post-ABLI grade and △ALBI level were significantly independent predictors of an inferior OS and RFS (P<0.05).
CONCLUSIONS: This study confirmed for the first time that post-ALBI grade and △ALBI could predict the prognosis of patients with HCC after hepatectomy.

Entities:  

Keywords:  Carcinoma; albumin-bilirubin (ALBI); hepatectomy; hepatocellular; prognosis

Year:  2019        PMID: 31555681      PMCID: PMC6736828          DOI: 10.21037/atm.2019.06.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  22 in total

1.  Perioperative safety and prognosis in hepatocellular carcinoma patients with impaired liver function.

Authors:  C Y Hsia; W Y Lui; G Y Chau; K L King; C C Loong; C W Wu
Journal:  J Am Coll Surg       Date:  2000-05       Impact factor: 6.113

Review 2.  Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials.

Authors:  J-H Zhong; H Li; L-Q Li; X-M You; Y Zhang; Y-N Zhao; J-Y Liu; B-D Xiang; G-B Wu
Journal:  Eur J Surg Oncol       Date:  2012-01-24       Impact factor: 4.424

Review 3.  Systematic review of actual 10-year survival following resection for hepatocellular carcinoma.

Authors:  Annelise M Gluer; Nicholas Cocco; Jerome M Laurence; Emma S Johnston; Michael J Hollands; Henry C C Pleass; Arthur J Richardson; Vincent W T Lam
Journal:  HPB (Oxford)       Date:  2012-02-28       Impact factor: 3.647

Review 4.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

Review 5.  Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD.

Authors:  François Durand; Dominique Valla
Journal:  J Hepatol       Date:  2004-12-24       Impact factor: 25.083

6.  Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Yuji Kaneoka; Atsuyuki Maeda
Journal:  J Gastroenterol Hepatol       Date:  2011-12       Impact factor: 4.029

7.  Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort.

Authors:  R T Poon; I O Ng; S T Fan; E C Lai; C M Lo; C L Liu; J Wong
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

8.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Authors:  Masao Omata; Laurentius A Lesmana; Ryosuke Tateishi; Pei-Jer Chen; Shi-Ming Lin; Haruhiko Yoshida; Masatoshi Kudo; Jeong Min Lee; Byung Ihn Choi; Ronnie T P Poon; Shuichiro Shiina; Ann Lii Cheng; Ji-Dong Jia; Shuntaro Obi; Kwang Hyub Han; Wasim Jafri; Pierce Chow; Seng Gee Lim; Yogesh K Chawla; Unggul Budihusodo; Rino A Gani; C Rinaldi Lesmana; Terawan Agus Putranto; Yun Fan Liaw; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2010-03-18       Impact factor: 6.047

9.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Hiroshi Imamura; Yutaka Matsuyama; Eiji Tanaka; Takao Ohkubo; Kiyoshi Hasegawa; Shinichi Miyagawa; Yasuhiko Sugawara; Masami Minagawa; Tadatoshi Takayama; Seiji Kawasaki; Masatoshi Makuuchi
Journal:  J Hepatol       Date:  2003-02       Impact factor: 25.083

10.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

View more
  8 in total

1.  Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection.

Authors:  Zhen Zhang; Jie Chen; Hanyu Jiang; Yi Wei; Xin Zhang; Likun Cao; Ting Duan; Zheng Ye; Shan Yao; Xuelin Pan; Bin Song
Journal:  Ann Transl Med       Date:  2020-07

2.  Preoperative Albumin-Bilirubin Grade as a Prognostic Predictor in Colorectal Cancer Patients Who Undergo Radical Resection.

Authors:  Ce Zhu; Xiang Wang; Xinxin Yang; Jing Sun; Bujian Pan; Weiteng Zhang; Xiaodong Chen; Xian Shen
Journal:  Cancer Manag Res       Date:  2020-12-01       Impact factor: 3.989

3.  Accuracy of conventional and novel scoring systems in predicting severity and outcomes of acute pancreatitis: a retrospective study.

Authors:  Qing Wu; Jie Wang; Mengbin Qin; Huiying Yang; Zhihai Liang; Guodu Tang
Journal:  Lipids Health Dis       Date:  2021-04-27       Impact factor: 3.876

4.  Development and Validation of Artificial Neural Networks for Survival Prediction Model for Patients with Spontaneous Hepatocellular Carcinoma Rupture After Transcatheter Arterial Embolization.

Authors:  Yiwen Qiu; Tao Wang; Xianwei Yang; Shu Shen; Yi Yang; Wentao Wang
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

Review 5.  The ALBI score: From liver function in patients with HCC to a general measure of liver function.

Authors:  Hidenori Toyoda; Philip J Johnson
Journal:  JHEP Rep       Date:  2022-08-18

6.  Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival.

Authors:  Yu Sun; Honghai Zhang; Jiang Long; Yonghong Zhang; Jiasheng Zheng; Chunwang Yuan
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

7.  Assessment in the Survival Outcome After Transarterial Chemoembolization Combined with Cryoablation for Hepatocellular Carcinoma (Diameter > 4cm) Based on the Albumin-Bilirubin Grade and Platelet-Albumin-Bilirubin ‎grade: ‎ A Preliminary Study.

Authors:  Zhimei Huang; Mengxuan Zuo; Jiayan Ni; Yangkui Gu; Tianqi Zhang; Yiquan Jiang; Shuiqing Zhuo; Chao An; Jinhua Huang
Journal:  Cancer Manag Res       Date:  2020-02-25       Impact factor: 3.989

8.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.